Topical Antibacterial Agents for Prevention of COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to determine whether intranasal application of aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo control in healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: Bill and Melinda Gates Foundation
• Treatments: Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination; Petrolatum

Criteria

Inclusion Criteria:

• Completion of written informed consent

• Covid-negative within 48 hours of enrollment based on PCR or Antigen test. If subjects are found to be positive, the PI will recommend appropriate follow-ups.

• In good general health as evidenced by medical history

• Ability to take Nasal medication and be willing to adhere to the nasal agent regimen

Exclusion Criteria:

• Participant with active nasal or respiratory symptoms.

• Participant with active or chronic respiratory nasal or respiratory infections and or is currently on antibiotics

• Participant who has been treated with oral or topical antibiotics with the past 14 days

• Participant who is on intranasal or oral corticosteroids or systemic immunosuppression medication

• Participant who has immunocompromised conditions such as rheumatological diseases, HIV, cancer on chemotherapy or biologic therapies.

• Participant who is on any intranasally applied medications (prescription or over the counter) including nonmedical nasal products and the use of Netipot or other nasal flush products.

• Participant with known allergic history to Neosporin (allergic history to neomycin or bacitracin or polymyxcin or pramoxine or the inactive ingredients that include cocoa butter, cottonseed oil, olive oil, sodium pyruvate, tocopheryl acetate and white petrolatum)

• Participant with known allergies to aminoglycoside antibiotics (neomycin, tobramycin, gentamycin, others)

• Participant with history of COVID-19 infection in the past 8 weeks.

• Participant who is pregnant